- Incannex Healthcare (IHL) teams up with Luxembourg-based Eurofins Scientific to manufacture two chewable products designed to treat nicotine and opioid addiction
- Eurofins will manufacture Incannex’s CannQuit products — chewing gum made with cannabidiol (CBD) to reduce other cravings
- Incannex and Eurofins will test the products in clinical trials designed to assess both the safety and efficacy of the chewables in treating addiction
- Incannex says the data collected from the clinical trials will form key components of future regulatory packages for the drug candidates
- Shares in Incannex Healthcare are trading at 25.5 cents at 11:37 am AEDT
Incannex Healthcare (IHL) has teamed up with Luxembourg-based Eurofins Scientific to manufacture two chewable products designed to treat nicotine and opioid addiction.
Eurofins, a contract development and manufacturing organisation (CDMO), will manufacture Incannex’s CannQuit products — chewing gum made with cannabidiol (CBD) to reduce other cravings.
CannQuit-N combines CBD and nicotine, and CannQuit-O combines CBD with an opioid antagonist or partial antagonist. The medicated gums deliver their ingredients rapidly but in a sustained manner so as to reduce cravings for nicotine and opioids for longer than other delivery methods.
Incannex and Eurofins will test the products in clinical trials designed to assess both the safety and efficacy of the chewables in treating addiction.
IHL Chief Scientific Officer Mark Bleackley said opioid and nicotine addictions were “significant health problems” and a major burden on health systems around the world.
“CannQuit products are designed to improve established therapies for the treatment of addiction,” Dr Bleackley said.
“They do this by adding CBD, which is known to reduce cravings and anxiety which is critical for breaking the addiction cycle.”
He said both CBD and the act of chewing had been shown to be conducive to stress and anxiety reduction.
Incannex said the data collected from the clinical trials on the quality and stability of the chewable products would form key components of future regulatory packages for the drug candidates, including investigational new drug (IND) and new drug application (NDA) filings with the US Food and Drug Administration.
IHL was transferred the CannQuit products and their associated patents and patent applications from its acquisition of APIRx Pharmaceuticals in August 2022.
Shares in Incannex Healthcare were trading at 25.5 cents at 11:37 am AEDT.
Be the first to comment